Page 51 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

ASCT
NR NR
? refractory and relapsed pts: IVAC +ASCT
NR
not upfront (n=1 after clinical not upfront (n=1 progression at end-of-treatment) progression) NR NR
NR
NR
Predictive value of interim PET in DLBCL
RT
Male
Table 1 Study- and patient characteristics
17·4% =event in methods numbers but no 43·2% 18·8% 29·9% 20·2% 34·0% NR NR NR d Treatment characteristics a Stage I/II non-bulky: 3-4x R-CHOP and IFRT Stage III/IV: R-CHOP21 MACOP-B (n=1) 85·8% R-CHOP21 R-CNOP (n=4) 9·8% R-CHOEP 11·2% R-HCVAD 82·0% R-CHOP 84·8% R-CHOP Stage First-line treatment 6·8% other 5·4% other 45% 21 day) (R-)CHOP21 50·4% 52·9% CHOP-like 88·2% R 55% 14 day R-CHOP R-CHOP (92·9% R
+ RT
86% R
57·3% 65·3% R-CHOP21 64·2%
62·6%
82·0%
III-IV bc‡cdc 49·7% 68·7%
54·3% 43·8%
111 /147 100% 58.9 (16-86) 45·0% 64·0% Stage I/II: 4x R- CHOP21 197 100% 46 (18-81) 60·4% 59·4% 14·2% R-CHOP14 52·9%
55·4%
52·7% ba bca 125 /138 100% 58.4(18-81) 54·3% 53·6% R-CHOP14 + 2R 57 (22-86)
56 (19-82)
62 (23-85)
mean 58·5
55 (IQR
49% > 61
44-64)
37% > 60
SD 14
No. of DLBCL Age median
PMBCL:
DLBCL:
97·2%
Patient characteristics
2·8%
100%
100%
147 100%
105 100%
150 100%
119 100%
patients (range)
294 /350
327 /361
b
112
retrospective
retrospective
retrospective
retrospective
retrospective
retrospective
prospective
prospective
prospective
prospective
design
Study
34
Study characteristics
Fan et al (2017)
35
De Oliveira
36 a 37
Mikhaeel et al
38
Mamot et al
39
40 a 41
42
43
First author,
Kim et al
Costa et al
Kong et al
Zhang et al
Dabaja et al
Mylam et al
Carr et al
year
(2017)
(2016)
(2016)
(2016)
(2015)
(2015)
(2014)
(2014)
(2014)
49
3